Supplementary File 1: Gamma-glutamyl Metformin and AMPK Signaling in Renal Cell Carcinoma

A 6.5 MB DOCX file containing research on a metformin prodrug for renal cell carcinoma therapy. The document, authored by Zheng Lv and last updated in May 2026, describes the development and antitumor activity of gamma-Glutamyl Metformin (γE-Met). It details how the prodrug leverages Gamma-glutamyl transpeptidase overexpression for targeted drug release and activation of the AMPK signaling pathway.

Use Cases

• Study targeted drug delivery mechanisms based on Gamma-glutamyl transpeptidase overexpression mentioned in the description
• Investigate AMPK signaling pathway activation in cancer therapy based on the described experimental results
• Compare the efficacy of prodrugs versus parent compounds based on the described retention time and growth inhibition data
• Identify potential biomarkers for renal cell tumors based on the mention of GGT overexpression

Strengths

• File size is explicitly stated as 6.5 MB, indicating a substantial document.
• License is clearly defined as CC-BY-4.0, allowing for open reuse.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset consists of a single DOCX file; data extraction and structuring require manual effort.

Provenance

Source

figshare

Freshness

Last updated 2026-05-07 04:46:37; freshness should be verified.